Mandate

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB (publ) in connection with the acquisition of Ultinous Zrt., a Swedish-Hungarian AI inventor, for a consideration of SEK 45 million, on a cash and debt free basis and assuming normalized working capital, which will be paid through an issue in kind entailing 9,000,000 new shares in Irisity at a subscription price of SEK 5.00 per share. In conjunction with the Acquisition Stockhorn Capital AB (founded by Gustav Andersson and Inna Kaushan) will invest SEK 45 million in Irisity through a directed share issue on the same terms as in the In-kind Issue, i.e., SEK 5.00 per share. The transaction will be subject to national FDI Regulation requiring approval from Swedish and Hungarian authorities and Iristy's EGM resolving to authorize the board of directors to resolve on the share issues. As part of the acquisition and directed share issue, Irisity and Stockhorn Capital will also enter into a loan agreement pursuant to which Stockhorn Capital will lend Irisity an amount of SEK 15 million.

Vinge's team consists of Anders Strid, Edin Agic and Fredrik Löwenclou.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026